Super-API Pipeline

DRGT is dedicated to develop a proprietary pipeline that consists of Super-API compositions of several blockbusters for oncology, pain, erectile dysfunction and other unmet medical needs.

Super-API drugs are being developed using DRGT’s Super-API technology platform. The developed Super-API compositions have unique structures with improved clinical utility. These compositions are protected by global composition of matter IPs.  

Proven benefits of the Super-APIs:

Regulatory
path
Super-API Indication Development Phase
Discovery
Preclinical
Phase I
BE Pivotal / Phase II-III
505(b)(2)
Bioequivalence
DRGT-45 Prostate cancer
EOP2 F2F meeting
DRGT-46 NSAID
EOP2 F2F meeting
DRGT-99 Erectile dysfunction
DRGT-18 Tuberous sclerosis complex
DRGT-119 Proctology
Ongoing Phase II
DRGT-128 Various cancers
DRGT-129 Multiple sclerosis
505(b)(1)
DRGT-124

Multiple sclerosis

Long life NCE
for partnership
505(b)(2)
DRGT-56 Cystic Fibroses
DRGT-76 Cystic Fibroses
DRGT-102 Cystic Fibroses
DRGT-73 Insomnia
DRGT-106 Non small cell lung cancer
DRGT-131 Non small cell lung cancer

Additional Super-API compounds are in discovery phase.